"GLP-1 and Suicidality: FDA & EMA Review Findings (2026)",

In mid-2023, scattered case reports of suicidal thoughts in people taking semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) prompted both U.S. and European regulators to open formal safety reviews. The question many people are searching is blunt and important: do GLP-1 weight-loss and diabetes drugs cause suicidal thoughts? Based on the evidence reviewed so far, the answer from both major regulators is the same: no clear causal link has been found. In January 2024 the U.S. FDA said its preliminary evaluation “has not found evidence” that GLP-1 medicines cause suicidal thoughts or actions^[1], and in January 2026 it requested removal of the suicidal-behavior warning from GLP-1 labels after a meta-analysis of 91 placebo-controlled trials found no increased risk^[2]. In April 2024 the European Medicines Agency's safety committee (PRAC) concluded the available evidence “does not support a causal association” between GLP-1 drugs and suicidal or self-injurious thoughts and actions^[3]. Those conclusions are backed by large electronic-health-record studies^[4][8], clinical-trial analyses^[5][6], and target-trial emulations^[7]. This article walks through exactly what was reviewed, what it found, and the real limits of that reassurance — without overstating it. If you take a GLP-1 and notice mood changes, see our companion piece on GLP-1 drugs, depression, and mood changes.

The honest summary

• How the reviews started. In July 2023, after case reports of suicidal and self-injurious thoughts in people using liraglutide and semaglutide, the EMA opened a review; the FDA had begun evaluating similar adverse-event reports around the same time^[1][3]. A 2024 pharmacovigilance analysis of European adverse-event reports had flagged a disproportionate number of suicide-related reports for these drugs — the kind of signal that triggers, but does not prove, a safety concern^[10].
• What the FDA concluded. In January 2024 the FDA said its preliminary review of trial data, observational studies, and adverse-event reports “has not found evidence” that GLP-1 medicines cause suicidal thoughts or actions — while noting the small number of events meant it could not definitively rule out a small risk^[1]. In January 2026, after a comprehensive meta-analysis of 91 placebo-controlled trials, the FDA requested removal of the suicidal-behavior warning from GLP-1 labels^[2].
• What the EMA concluded. In April 2024 the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded the evidence “does not support a causal association” between GLP-1 drugs (dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide) and suicidal or self-injurious thoughts and actions, and decided no product-information update was warranted^[3].
• The big real-world studies agreed. A cohort of more than 240,000 people on semaglutide found no higher — and in some analyses a lower — risk of suicidal ideation versus other weight or diabetes medicines^[4]. A target-trial emulation in older adults with diabetes and a propensity-weighted European cohort both found no clear increased risk^[7][8].
• The trial data agreed too. In the SELECT cardiovascular trial (17,604 people) psychiatric adverse events were not increased with semaglutide^[6], and a pooled analysis of the STEP 1, 2, 3, and 5 weight-management trials found no increase in depression or suicidal ideation — and a small decrease in depressive symptoms — versus placebo^[5].
• The honest limits. Suicidal events are rare, so even large studies have wide confidence intervals and cannot fully exclude a small risk^[7][9]. Most trials excluded people with active major psychiatric illness^[5], so the data say less about that group. “No causal link found” is not the same as “impossible” — which is why monitoring mood, especially early on, still matters.

Why regulators looked into this in the first place

Safety reviews of this kind usually begin with a signal — a pattern in spontaneous adverse-event reports that warrants a closer look but, on its own, proves nothing about cause and effect. Here, the signal came from case reports submitted to regulators in 2023. A pharmacovigilance analysis of the European EudraVigilance database (Tobaiqy 2024^[10]) examined adverse-event reports for semaglutide, liraglutide, and tirzepatide and found that, among the psychiatric reports, suicide-related events were prominent — including reports of suicidal ideation, attempts, and a small number of deaths. The authors were careful to note this is a disproportionality finding, not proof of causation: spontaneous reporting databases are vulnerable to media-driven reporting, lack denominators, and cannot account for the underlying mental-health burden of obesity and diabetes. But a signal like that is precisely what regulators are obligated to investigate, and in July 2023 the EMA formally opened its review^[3].

It is also worth being honest about the context. Obesity and type 2 diabetes are themselves associated with higher rates of depression and suicidal thoughts, independent of any medication. That makes the central question harder: if someone on a GLP-1 has suicidal thoughts, is it the drug, the underlying condition, life circumstances, or coincidence? Untangling that is exactly what the larger controlled studies below were designed to do — and why a handful of case reports, however serious, could not settle the matter on their own.

What the FDA reviewed and concluded

On January 11, 2024, the FDA issued a Drug Safety Communication updating its ongoing evaluation. Its stated finding: the preliminary evaluation “has not found evidence that use of these medicines causes suicidal thoughts or actions.” The agency had reviewed reports in its FAERS adverse-event system and found that, because the information was often limited and the events can be influenced by other factors, the reports “did not demonstrate a clear relationship” with GLP-1 use. Its reviews of clinical trials — including large outcome studies and observational studies — “did not find an association.” Crucially, the FDA added an honest caveat: because the number of suicidal events was small in both the GLP-1 and comparison groups, it could not definitively rule out that a small risk may exist, and it would continue to investigate^[1]. The drugs covered included semaglutide, tirzepatide, and liraglutide.

The FDA then did what good pharmacovigilance demands: it gathered more precise data. To narrow the uncertainty, it conducted a comprehensive meta-analysis pooling roughly 91 placebo-controlled clinical trials across GLP-1 development programs (more than 100,000 participants), specifically comparing rates of suicidal ideation and behavior on GLP-1 drugs versus placebo. That analysis showed no increased risk of suicidal ideation/behavior or other psychiatric adverse events. On that basis, in January 2026 the FDA requested that manufacturers remove the suicidal-behavior and ideation warning from the labeling of affected GLP-1 medicines, stating it “did not identify an increased risk of suicidal ideation or behavior” with these drugs^[2].

What the EMA's safety committee concluded

Europe's review ran in parallel. After its July 2023 start, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed non-clinical studies, clinical trials, post-marketing surveillance, and two large electronic-health-record studies. At its meeting on 8–11 April 2024, the PRAC concluded that “the available evidence does not support a causal association” between the GLP-1 receptor agonists it reviewed — dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide — and suicidal and self-injurious thoughts and actions. One of the studies it weighed examined suicidal-thought incidence in people with overweight and type 2 diabetes treated with semaglutide versus non-GLP-1 medicines and found no causal association; a second EMA-commissioned EHR study of suicide-related and self-injury events in type 2 diabetes likewise did not support a causal link. The committee concluded that no update to the product information was warranted^[3]. The UK's MHRA reached a similar conclusion in its own review.

The large real-world studies behind those conclusions

The regulatory conclusions did not rest on opinion — they rested on some of the largest observational datasets assembled on this question. The most cited is Wang and colleagues (2024, Nature Medicine), a retrospective study of electronic health records from a network of U.S. health systems. Among roughly 240,000 patients with overweight or obesity, semaglutide was associated with a lower risk of first-time and recurrent suicidal ideation compared with other anti-obesity medications; the finding was replicated in a cohort of about 1.6 million patients with type 2 diabetes^[4]. The authors stressed this is an association, not proof of a protective effect, but it directly contradicts the idea that semaglutide drives suicidal thoughts.

Two further studies sharpened the picture using methods designed to mimic a randomized trial. Tang and colleagues (2024, Annals of Internal Medicine) ran a target-trial emulation in U.S. Medicare beneficiaries (older adults with type 2 diabetes), comparing GLP-1 drugs to SGLT2 inhibitors and DPP-4 inhibitors. The hazard ratios for suicidal ideation and behaviors were close to 1 and not statistically significant (1.07 vs. SGLT2is; 0.94 vs. DPP4is), with the authors concluding no clear increased risk — while candidly noting the estimates were imprecise and a modest risk could not be excluded^[7]. A propensity-weighted European population-based cohort (Hurtado 2024, Diabetologia) in people with diabetes and obesity similarly found no evidence of increased risk versus SGLT2 inhibitors (hazard ratio about 1.04), again with wide confidence intervals reflecting how rare these events are^[8].

Finally, a 2025 systematic review and meta-analysis (Bushi 2025, Diabetes/Metabolism Research and Reviews) pooled the available studies and found no statistically significant association between GLP-1 use and suicidal ideation or behavior — but flagged high statistical heterogeneity and reliance on pharmacovigilance data as reasons to interpret the pooled estimate cautiously and keep monitoring patients^[9]. That caveat is the recurring theme of this literature: the direction of evidence is reassuring, but the rarity of events keeps the door open a crack.

What the major clinical trials showed

Randomized trials are the cleanest evidence because treatment is assigned by chance. In the SELECT cardiovascular outcomes trial (Lincoff 2023, New England Journal of Medicine), 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes were randomized to semaglutide 2.4 mg or placebo. Semaglutide was not associated with higher rates of psychiatric disorders, and overall serious adverse events were actually fewer than with placebo^[6].

For the weight-management dose specifically, Wadden and colleagues (2024, JAMA Internal Medicine) performed a pre-specified pooled analysis of the STEP 1, 2, 3, and 5 trials of semaglutide 2.4 mg in people without known major psychiatric illness. Using validated tools — the PHQ-9 for depressive symptoms and the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation/behavior — they found semaglutide did not increase the risk of depression or suicidal ideation versus placebo. Suicidal ideation or behavior occurred in 1% or fewer of participants in both groups with no meaningful imbalance, and depressive symptoms improved slightly more on semaglutide (a small, likely not clinically meaningful PHQ-9 difference)^[5]. The important caveat: these trials excluded people with recent major depression or other severe psychiatric disorders, so they say little about that higher-risk population — which is why ongoing monitoring is recommended for everyone, and especially for people with a psychiatric history.

What this means for you

• The weight of evidence is reassuring. Two major regulators (FDA and EMA), large EHR cohorts of hundreds of thousands to millions of patients, target-trial emulations, and the SELECT and STEP randomized trials all point the same way: no clear evidence that GLP-1 drugs cause suicidal thoughts or behavior^{[1][3][4][5][6][7]}.
• “No causal link found” is not “zero risk.” Because suicidal events are rare, even big studies can't fully exclude a small risk, and most trials excluded people with active major psychiatric illness^[5][7][9]. Reassurance and continued vigilance are not contradictory.
• Monitor your mood — especially early and after dose changes. Any significant medical change, including rapid weight loss or appetite suppression, can affect how you feel. Track changes in mood, sleep, and outlook, and tell your prescriber about a personal or family history of depression or suicidal thoughts before starting.
• Don't stop a GLP-1 abruptly on your own over this. If you have concerns, raise them with your prescriber rather than self-discontinuing — stopping diabetes medication suddenly carries its own risks. There may be a plan that monitors mood while keeping treatment going.
• Seek help immediately for warning signs. Thoughts of self-harm, hopelessness, or being a burden are medical emergencies, not side effects to “wait out.” Use the 988 Suicide & Crisis Lifeline (call or text 988 in the U.S.) or your local emergency number.

Bottom line

After case reports raised a concern in 2023, both U.S. and European regulators reviewed the evidence in depth. The FDA found no evidence that GLP-1 medicines cause suicidal thoughts or actions, and by January 2026 — backed by a 91-trial meta-analysis showing no increased risk — requested removal of the suicidal-behavior warning from GLP-1 labels^[1][2]. The EMA's PRAC concluded the evidence does not support a causal association and left the product information unchanged^[3]. Those conclusions are reinforced by large electronic-health-record cohorts^[4][8], target-trial emulations^[7], a meta-analysis^[9], and the SELECT and STEP randomized trials^[5][6]. The honest framing is this: the evidence is reassuring but not absolute — suicidal events are rare, and people with active psychiatric illness were under-studied. So the right posture is reassurance with vigilance: watch your mood, keep your prescriber in the loop, and never hesitate to seek crisis help.

This article is educational and is not medical advice. Every claim above is sourced to an FDA Drug Safety Communication, the EMA/PRAC meeting record, or a peer-reviewed study indexed in PubMed, each verified against the live source before publication. Regulatory conclusions are reported precisely, including their stated limits. If you are struggling with thoughts of suicide or self-harm, call or text 988 (U.S. Suicide & Crisis Lifeline) or contact your local emergency services. Discuss any mood changes on a GLP-1 with your prescriber or a mental-health professional.